Benzinga | Oct 11, 2021 04:47AM EDT

Raymond James Upgrades ChemoCentryx to Strong Buy, Raises Price Target to $107

Raymond James analyst Steven Seedhouse upgrades ChemoCentryx (NASDAQ:CCXI) from Outperform to Strong Buy and raises the price target from $62 to $107.